Abstracts Archive - Page 1588 of 2607 - ACR Meeting Abstracts

Abstract Number: 88 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
Amir Orandi¹, Vikas Dharnidharka², Noor Al-Hammadi³ and Kevin Baszis¹, ¹Pediatric Rheumatology, Washington University in St. Louis School of Medicine, Saint Louis, MO, ²Pediatric Nephrology, Washington University in St. Louis School of Medicine, Saint Louis, MO, ³Division of Biostatistics, Washington University in St. Louis School of Medicine, St Louis, MO
Background/Purpose: Calcinosis develops in an estimated 40% of patients with Juvenile Dermatomyositis (JDM). Conflicting studies have not definitively identified actionable risk factors or demonstrated that…
Abstract Number: 130 • 2017 Pediatric Rheumatology Symposium
Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin
Dirk Holzinger¹, Carolin Pretzer², Maria Miranda-Garcia^2,3, Hans Huppertz⁴, Gerd Horneff⁵, Johannes Peter Haas⁶, Gerd Ganser⁷, Jasmin B. Kuemmerle-Deschner⁸, Michael Frosch⁹, Johannes Roth¹⁰ and Dirk Foell², ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ³Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institute, Langen, Germany, ⁴Prof Hess Children’s Hospital Bremen, Bremen, Germany, ⁵Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, ⁶Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Pediatric Pain Centre,, Children's and Adolescents' Hospital Datteln, Datteln, Germany, ¹⁰Institute of Immunology, University of Muenster, Muenster, Germany
Background/Purpose: The differential diagnosis of fever of unknown origin (FUO) is a major challenge in pediatrics especially for differentiation of systemic-onset juvenile idiopathic arthritis (SJIA)…
Abstract Number: 46 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Kristina Unnebrink⁴ and Jaclyn K. Anderson⁵, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…
Abstract Number: 134 • 2017 Pediatric Rheumatology Symposium
Akkermansia Muciniphila May Be Permissive to Arthritis in the K/BxN Mouse Model of Arthritis
Matthew L. Stoll¹, Casey D Morrow², Pamela Weiss³, Jennifer E. Weiss⁴, Lennard W. Duck⁵, Charles O. Elson⁶, Randy Q. Cron⁷, Elliot J. Lefkowitz⁸, Ranjit Kumar⁹ and Trenton R. Schoeb¹⁰, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Hackensack Univ Med Ctr, Hackensack, NJ, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Dept of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Microbiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Center for Clinical and Translational Sciences, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Genetics and Comparative Pathology Laboratory, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Studies have identified abnormalities in the microbiota of patients with arthritis. To evaluate the pathogenicity of human microbiota, we performed fecal microbial transplantation (FMT)…
Abstract Number: 41 • 2017 Pediatric Rheumatology Symposium
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet Ramanan³, Rubén Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson⁶, Heinrike Schmeling⁷, Jordi Anton⁸, Kirsten Minden⁹, Joy Hsu¹⁰, Kamal Bharucha¹¹, Sunethra Wimalasundera¹², Alysha K. Kadva¹³, Ruchi Upmanyu¹², Navita L. Mallalieu¹⁰, Daniel Lovell⁶ and Fabrizio De Benedetti¹⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁸Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Charité – University of Medicine Berlin, Berlin, Germany, ¹⁰Roche Innovation Center, New York, NY, ¹¹Genentech, South San Francisco, CA, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹³Genentech, San Francisco, CA, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients (pts) with polyarticular-course juvenile idiopathic…
Abstract Number: 136 • 2017 Pediatric Rheumatology Symposium
14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis
Austin Dalrymple^1,2,3, Paul Tuttle IV⁴, Lance Feller⁵, Olga S. Zhukov⁶, Robert J. Lagier⁷, Robert Bridgforth⁸, Gary J Williams⁹, Joanna Popov¹⁰, Stanley J. Naides⁶ and Terry Moore¹¹, ¹Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO, ²Division of Adult and Pediatric Rheumatology, Saint Louis University, St Louis, MO, ³Division of Rheumatology and Pediatric Rheumatology, Saint Louis University, St Louis, MO, ⁴Saint Louis University, Saint Louis, MO, ⁵Former fellow, Saint Louis University, Watertown, ME, ⁶Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁷Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁸nichols Institute, Quest Diagnostics, San Juan Capistrano, CA, ⁹Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ¹⁰Immunology, Quest Diagnostics, San Jian Capistrano, CA, ¹¹Rheumatology, Saint Louis University, St. Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 37 • 2017 Pediatric Rheumatology Symposium
Increased Involvement of Teenagers with Juvenile Idiopathic Arthritis in Treatment Decisions Using Medication Choice Cards: Preliminary Report from a Case-Control Study
Suhas Ganguli¹, Sarah Hoffmann², Meredith Akerman³, Heather Walters⁴ and Beth Gottlieb⁵, ¹Pediatrics, Cohen Children's Medical Center of New York, Lake Success, NY, ²Children’s Hospital at Richmond at Virginia Commonwealth University, Richmond, VA, ³The Feinstein Institute for Medical Research, Great Neck, NY, ⁴Cohen Children's Medical Center of New York, Lake Success, NY, ⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY
Background/Purpose: Shared Decision Making (SDM) is an interactive process whereby the clinician-patient-parent triad arrives at a treatment decision after reviewing treatment goals, best available medical…
Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Tommy Gerschman¹, Jordan Raugust², Julia Brooks³, Nicole Johnson¹, Nadia Luca⁴, Rebeka Stevenson¹, Heinrike Schmeling⁵, Paivi Miettunen¹ and Susanne Benseler⁴, ¹Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, ³Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁵University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
Abstract Number: 4 • 2017 Pediatric Rheumatology Symposium
Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome
Lehn K. Weaver¹, Chhanda Biswas¹, Niansheng Chu¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Targeting host-microbiota interactions to limit production of pathogenic myeloid cells that fuel chronic inflammatory responses is of therapeutic interest. Recent evidence suggests that this may…
Abstract Number: 73 • 2017 Pediatric Rheumatology Symposium
Factors Associated with Etoposide Usage in Children with Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
AnnaCarin Horne¹, Francesca Minoia², Randy Q. Cron³ and Angelo Ravelli⁴, ¹Karolinska University Hospital Solna, Stockholm, Sweden, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Genova, Genova, Italy
Background/Purpose: Although macrophage activation syndrome (MAS) has been reported in association with almost all rheumatic diseases, it is by far most common in systemic juvenile…
Abstract Number: 10 • 2017 Pediatric Rheumatology Symposium
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Keith A. Sikora¹, Joshua R. Bennett¹, Zuoming Deng², Wanxia Li Tsai³, April D. Brundidge³, Fatemeh Navid³, Gerlinde Layh-Schmitt³, Eric Hanson⁴, Massimo G. Gadina⁵, Louis M. Staudt⁶, Thomas A. Griffin⁷ and Robert Colbert³, ¹Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Translational Immunology, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁷Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC
Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function…
Abstract Number: 65 • 2017 Pediatric Rheumatology Symposium
Barriers at School for Children with Juvenile Idiopathic Arthritis (JIA) –A Patient Reported Outcome
Kelsey Chomistek¹, Nicole Johnson², Rebeka Stevenson², Nadia Luca³, Paivi Miettunen², Susanne Benseler³, Dwaraka Veeramreddy⁴ and Heinrike Schmeling⁵, ¹Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ²Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ³Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Department of Pediatrics/Alberta Children's Hospital, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁵University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Few studies in children with chronic illnesses/disability have reported challenges faced by patients at school. Therefore, the objective of this study is to identify…
Abstract Number: 128 • 2017 Pediatric Rheumatology Symposium
Treatment Response in Polyarticular Juvenile Idiopathic Arthritis is Associated With Transcriptional Changes and Chromatin Reorganization in CD4+ T cells
Evan Tarbell¹, Kaiyu Jiang², Yanmin Chen², Tao Liu³ and James Jarvis⁴, ¹Biochemistry, University at Buffalo, Buffalo, NY, ²Pediatrics, University at Buffalo, Buffalo, NY, ³Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁴Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: The polyarticular form of JIA is associated with well-documented transcriptional abnormalities in peripheral blood cells. The abnormalities can be observed in neutrophils, peripheral blood…
Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Treatment Outcomes in Down’s Arthropathy
Jordan T. Jones¹ and Leena Danawala², ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].